Revacept: Collagen GP VI receptor inhibitor, a new & a formidable target for antiplatelet action

Antiplatelet drugs play an important role in the prevention as well as treatment of cardiovascular diseases like coronary artery disease and stroke. Many of the currently available antiplatelet drugs face limitations due to safety and efficacy issues. A new antiplatelet drug, revacept i.e. a collagen receptor antagonist, has been shown to reduce platelet adhesion by blocking GP VI-dependent pathways without increasing the risk of bleeding complications and without affecting the general hemostasis.